Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04136171




Registration number
NCT04136171
Ethics application status
Date submitted
21/10/2019
Date registered
23/10/2019
Date last updated
23/01/2024

Titles & IDs
Public title
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Scientific title
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Secondary ID [1] 0 0
2019-002835-27
Secondary ID [2] 0 0
ION-682884-CS2
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Eplontersen
Treatment: Drugs - Placebo

Experimental: Eplontersen - Eplontersen by subcutaneous injection once every 4 weeks

Placebo Comparator: Placebo - Eplontersen-matching placebo by subcutaneous injection once every 4 weeks


Treatment: Drugs: Eplontersen
Eplontersen by subcutaneous injection

Treatment: Drugs: Placebo
Eplontersen-matching placebo by subcutaneous injection
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Composite Outcome of Cardiovascular (CV) Mortality and Recurrent CV Clinical Events up to Week 140
Timepoint [1] 0 0
Baseline up to Week 140
Secondary outcome [1] 0 0
Change From Baseline in the 6-minute Walk Test (6MWT) Distance at Week 121
Timepoint [1] 0 0
Baseline to Week 121
Secondary outcome [2] 0 0
Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores at Week 121
Timepoint [2] 0 0
Baseline to Week 121
Secondary outcome [3] 0 0
CV Clinical Events up to Week 140
Timepoint [3] 0 0
Baseline up to Week 140
Secondary outcome [4] 0 0
CV Mortality up to Week 140
Timepoint [4] 0 0
Baseline up to Week 140
Secondary outcome [5] 0 0
All-Cause Mortality up to Week 140
Timepoint [5] 0 0
Baseline up to Week 140

Eligibility
Key inclusion criteria
- Females must be non-pregnant and non-lactating, and either surgically sterile or
post-menopausal or abstinent. If engaged in sexual relations of child-bearing
potential, agree to use 1 highly effective contraceptive method

- Males must be surgically sterile or, abstinent or, if engaged in sexual relations with
a woman of child-bearing potential, the participant or the participant's non-pregnant
female partner must be using a highly effective contraceptive method

- Amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or
equivalent) staining OR technetium scintigraphy (99mTc -3,3-diphosphono-1,2-
propanodicarboxylic acid [DPD-Tc], 99m Tc-pyrophosphate [PYP-Tc], or 99m
Tc-hydroxymethylene-diphosphonate [HMDP-Tc]) with Grade 2 or 3 cardiac uptake in the
absence of abnormal light chains ratio, centrally confirmed

- End-diastolic interventricular septum thickness of > 12 millimeters (mm) on Screening
echocardiogram

- New York Heart Association (NYHA) class I-III
Minimum age
18 Years
Maximum age
90 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Acute coronary syndrome, unstable angina, stroke, transient ischemic attack (TIA),
coronary revascularization, cardiac device implantation, cardiac valve repair, or
major surgery within 3 months of Screening

- Cardiomyopathy not primarily caused by ATTR-CM, for example, cardiomyopathy due to
hypertension, valvular heart disease, or ischemic heart disease

- Monoclonal gammopathy of undetermined significance (MGUS) and/or alterations in
immunoglobulin free light chain (FLC) ratio unless fat, bone marrow, or heart biopsy
confirming the absence of light chain and the presence of TTR protein by mass
spectrometry or immunoelectron microscopy. For participants with chronic kidney
disease (CKD) and without presence of monoclonal protein in blood and urine, the
acceptable FLC ratio is 0.26-2.25. Results different from that may be discussed with
local hematologist, Investigator and Medical Monitor if the risks associated with the
biopsy outweigh the benefits

- Prior liver or heart transplant, and/or Left Ventricular Assist Device (LVAD) or
anticipated liver transplant or LVAD within 1 year after randomization

- Current or previous treatment with Tegsedi™ (inotersen) or Onpattro™ (patisiran) or
other oligonucleotide or ribonucleic acid (RNA) therapeutic (including small
interfering ribonucleic acid [siRNA]; does not apply to COVID-19 mitochondrial [mRNA]
vaccinations)

- Current treatment with diflunisal, doxycycline, with or without ursodeoxycholic acid,
and/or non-dihydropyridine calcium-channel blocker (e.g., verapamil, diltiazem).
Participants receiving any of these agents must respect a wash-out period of 14 days
before randomization.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/03/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/11/2025
Actual
Sample size
Target
Accrual to date
Final
1438
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,West AustraliaWA
Recruitment hospital [1] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [2] 0 0
The Westmead Institute for Medical Research - Westmead
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 0 0
Advara Heartcare - Leabrook
Recruitment hospital [5] 0 0
Royal Hobart Hospital - Hobart
Recruitment hospital [6] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [7] 0 0
Advara HeartCare Murdoch - Murdoch
Recruitment hospital [8] 0 0
GenesisCare Murdoch - Murdoch
Recruitment hospital [9] 0 0
Advara HeartCare - Joondalup
Recruitment hospital [10] 0 0
GenesisCare Joondalup - Joondalup
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
NSW 2145 - Westmead
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
5068 - Leabrook
Recruitment postcode(s) [5] 0 0
7000 - Hobart
Recruitment postcode(s) [6] 0 0
3128 - Box Hill
Recruitment postcode(s) [7] 0 0
6150 - Murdoch
Recruitment postcode(s) [8] 0 0
6027 - Joondalup
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
New York
Country [17] 0 0
United States of America
State/province [17] 0 0
North Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Ohio
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Tennessee
Country [23] 0 0
United States of America
State/province [23] 0 0
Texas
Country [24] 0 0
United States of America
State/province [24] 0 0
Utah
Country [25] 0 0
United States of America
State/province [25] 0 0
Virginia
Country [26] 0 0
United States of America
State/province [26] 0 0
Washington
Country [27] 0 0
United States of America
State/province [27] 0 0
Wisconsin
Country [28] 0 0
Argentina
State/province [28] 0 0
Buenos Aires
Country [29] 0 0
Austria
State/province [29] 0 0
Styria
Country [30] 0 0
Austria
State/province [30] 0 0
Tyrol
Country [31] 0 0
Austria
State/province [31] 0 0
Vienna
Country [32] 0 0
Belgium
State/province [32] 0 0
Limburg
Country [33] 0 0
Belgium
State/province [33] 0 0
West-Vlaanderen
Country [34] 0 0
Brazil
State/province [34] 0 0
Campinas
Country [35] 0 0
Brazil
State/province [35] 0 0
Porto Alegre
Country [36] 0 0
Brazil
State/province [36] 0 0
Ribeirão Preto
Country [37] 0 0
Brazil
State/province [37] 0 0
São Paulo
Country [38] 0 0
Canada
State/province [38] 0 0
Alberta
Country [39] 0 0
Canada
State/province [39] 0 0
British Columbia
Country [40] 0 0
Canada
State/province [40] 0 0
Ontario
Country [41] 0 0
Canada
State/province [41] 0 0
Quebec
Country [42] 0 0
Czechia
State/province [42] 0 0
South Moravian
Country [43] 0 0
Czechia
State/province [43] 0 0
Prague
Country [44] 0 0
Denmark
State/province [44] 0 0
Hovedstaden
Country [45] 0 0
Denmark
State/province [45] 0 0
Syddanmark
Country [46] 0 0
France
State/province [46] 0 0
Occitanie
Country [47] 0 0
France
State/province [47] 0 0
Créteil
Country [48] 0 0
France
State/province [48] 0 0
La Roche-sur-Yon
Country [49] 0 0
France
State/province [49] 0 0
Marseille
Country [50] 0 0
France
State/province [50] 0 0
Pessac
Country [51] 0 0
France
State/province [51] 0 0
Saint-Herblain
Country [52] 0 0
Germany
State/province [52] 0 0
Saarland
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Germany
State/province [54] 0 0
Heidelberg
Country [55] 0 0
Germany
State/province [55] 0 0
Köln
Country [56] 0 0
Germany
State/province [56] 0 0
Münster
Country [57] 0 0
Germany
State/province [57] 0 0
Würzburg
Country [58] 0 0
Greece
State/province [58] 0 0
Athens
Country [59] 0 0
Israel
State/province [59] 0 0
Haifa
Country [60] 0 0
Israel
State/province [60] 0 0
Jerusalem
Country [61] 0 0
Israel
State/province [61] 0 0
Rehovot
Country [62] 0 0
Italy
State/province [62] 0 0
Ancona
Country [63] 0 0
Italy
State/province [63] 0 0
Bologna
Country [64] 0 0
Italy
State/province [64] 0 0
Florence
Country [65] 0 0
Italy
State/province [65] 0 0
Padua
Country [66] 0 0
Italy
State/province [66] 0 0
Pavia
Country [67] 0 0
Italy
State/province [67] 0 0
Pisa
Country [68] 0 0
Italy
State/province [68] 0 0
Roma
Country [69] 0 0
Japan
State/province [69] 0 0
Ehime
Country [70] 0 0
Japan
State/province [70] 0 0
Fukuoka
Country [71] 0 0
Japan
State/province [71] 0 0
Hokkaido
Country [72] 0 0
Japan
State/province [72] 0 0
Hukuoka
Country [73] 0 0
Japan
State/province [73] 0 0
Kyoto
Country [74] 0 0
Japan
State/province [74] 0 0
Nagano
Country [75] 0 0
Japan
State/province [75] 0 0
Okayama
Country [76] 0 0
Japan
State/province [76] 0 0
Osaka
Country [77] 0 0
Japan
State/province [77] 0 0
Shizuoka
Country [78] 0 0
Japan
State/province [78] 0 0
Tokyo
Country [79] 0 0
Japan
State/province [79] 0 0
Kumamoto
Country [80] 0 0
Poland
State/province [80] 0 0
Kraków
Country [81] 0 0
Poland
State/province [81] 0 0
Warszawa
Country [82] 0 0
Portugal
State/province [82] 0 0
Guimarães
Country [83] 0 0
Portugal
State/province [83] 0 0
Lisbon
Country [84] 0 0
Portugal
State/province [84] 0 0
Porto
Country [85] 0 0
Puerto Rico
State/province [85] 0 0
San Juan
Country [86] 0 0
Spain
State/province [86] 0 0
Barcelona
Country [87] 0 0
Spain
State/province [87] 0 0
Majadahonda
Country [88] 0 0
Spain
State/province [88] 0 0
Murcia
Country [89] 0 0
Spain
State/province [89] 0 0
Santiago de Compostela
Country [90] 0 0
Sweden
State/province [90] 0 0
Göteborg
Country [91] 0 0
Sweden
State/province [91] 0 0
Skellefteå
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Scotland
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Wales
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Edgbaston
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Hexham
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Liverpool
Country [97] 0 0
United Kingdom
State/province [97] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Ionis Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM
receiving available standard of care (SoC). For more information, please visit
https://www.cardio-ttransform.com.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04136171
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04136171